All In Biotech

Drug Trial Radar · NCT06820463

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 390 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

390

Planned (sponsor's estimate)

Start

Apr 24, 2025

Primary completion

Mar 2028

Study completion Apr 2028

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Feb 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of mCRC. Fluorouracil and leucovorin are drugs approved for the treatment of mCRC. This study will be divided into two stages, with the first stage treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. Participants will then be randomized into 3 groups called treatment arms where one group will receive one of two optimized doses of telisotuzumab adizutecan from the dose escalation phase with FOLFOX and bevacizumab or 5FU/LV and panitumumab, or a comparator of FOLFOX and bevacizumab or panitumumab. Approximately 390 adult participants with mCRC will be enrolled in the study in 100 sites worldwide. In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive FOLFOX or receive 5FU/LV, but with one of two optimized doses of telisotuzumab adizutecan, or a comparator of FOLFOX and bevacizumab/pantitumumab. The study will run for a duration of approximately 6 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • Telisotuzumab AdizutecanDrug

    Intravenous (IV) Infusion

  • FluorouracilDrug

    IV Infusion; IV Injection

  • OxaliplatinDrug

    IV Infusion

  • LeucovorinDrug

    IV Infusion; IV Injection

  • BevacizumabDrug

    IV Infusion

  • PanitumumabDrug

    IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response (OR) as Assessed by the Investigator confirmed complete response (CR) or partial response (PR) as assessed by the investigator per response evaluation criteria in solid tumors (RECIST), version 1.1.Time frame: Up to 24 Weeks
  2. Number of Participants with Adverse Events (AE)sTime frame: Up to Approximately 6 Years

Locations

82 sites in 15 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center /ID# 270255

    Duarte, California · Recruiting

  • UCLA - Santa Monica /ID# 270621

    Santa Monica, California · Recruiting

  • Yale New Haven Hospital /ID# 270565

    New Haven, Connecticut · Recruiting

  • AdventHealth Orlando /ID# 270789

    Orlando, Florida · Recruiting

  • Northwest Georgia Oncology Centers /ID# 270245

    Marietta, Georgia · Recruiting

  • University of Chicago Medical Center /ID# 271688

    Chicago, Illinois · Recruiting

  • Hope And Healing Cancer Services /ID# 271562

    Hinsdale, Illinois · Recruiting

  • Dana-Farber Cancer Institute /ID# 270624

    Boston, Massachusetts · Recruiting

  • University Of Michigan /ID# 270790

    Ann Arbor, Michigan · Recruiting

  • Saint Lukes Hospital of Kansas City /ID# 270633

    Kansas City, Missouri · Recruiting

  • Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271646

    Omaha, Nebraska · Recruiting

  • University of North Carolina at Chapel Hill /ID# 267786

    Chapel Hill, North Carolina · Recruiting

  • Oncology Hematology Care - Eastgate /ID# 271493

    Cincinnati, Ohio · Recruiting

  • Texas Oncology - Austin Midtown /ID# 271354

    Austin, Texas · Recruiting

  • Texas Oncology - Deke Slayton Cancer Center /ID# 271355

    Webster, Texas · Recruiting

  • Virginia Cancer Specialists - Fairfax /ID# 271351

    Fairfax, Virginia · Recruiting

  • University Of Washington /ID# 271298

    Seattle, Washington · Recruiting

  • Macquarie University /ID# 271514

    Sydney, New South Wales, Australia · Recruiting

  • Mater Misericordiae /ID# 270694

    South Brisbane, Queensland, Australia · Recruiting

  • The Queen Elizabeth Hospital /ID# 270693

    Woodville South, South Australia, Australia · Recruiting

  • Austin Health /ID# 270692

    Heidelberg, Victoria, Australia · Recruiting

  • One Clinical Research /ID# 270695

    Nedlands, Western Australia, Australia · Recruiting

  • Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 268874

    Salzburg, Austria · Recruiting

  • Medizinische Universitaet Wien /ID# 268872

    Vienna, Austria · Recruiting

  • Medizinische Universitaet Graz /ID# 268876

    Graz, Styria, Austria · Recruiting

  • Instituto D Or De Pesquisa E Ensino - Regional Sao Paulo /ID# 270546

    São Paulo, Brazil · Recruiting

  • Nucleo De Pesquisa Clinica Da Rede Sao Camilo /ID# 272311

    São Paulo, Brazil · Recruiting

  • Hospital Sao Rafael /ID# 271681

    Salvador, Estado de Bahia, Brazil · Recruiting

  • Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 270147

    Ijuí, Rio Grande do Sul, Brazil · Recruiting

  • Hospital De Amor /ID# 271874

    Barretos, São Paulo, Brazil · Recruiting

  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 271651

    São José do Rio Preto, São Paulo, Brazil · Recruiting

  • Arthur J.E Child Comprehensive Cancer Centre /ID# 269809

    Calgary, Alberta, Canada · Recruiting

  • Cross Cancer Institute. /ID# 272711

    Edmonton, Alberta, Canada · Recruiting

  • London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 270680

    London, Ontario, Canada · Recruiting

  • Princess Margaret Cancer Centre /ID# 268715

    Toronto, Ontario, Canada · Recruiting

  • Universite de Montreal - Hopital Maisonneuve-Rosemont /ID# 271368

    Montreal, Quebec, Canada · Recruiting

  • Masarykuv onkologicky ustav v Brne /ID# 268779

    Brno, Czechia · Recruiting

  • Fakultni nemocnice Hradec Kralove - Sokolska /ID# 268773

    Hradec Králové, Czechia · Recruiting

  • Vseobecna Fakultni nemocnice v Praze /ID# 268775

    Prague, Praha 17, Czechia · Recruiting

  • Fakultni nemocnice Motol a Homolka /ID# 268776

    Prague, Praha 5, Czechia · Recruiting

Showing 40 of 82 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.